Evidence map›Paper›PMID 42279327›Full record

ArticleCancers2026

Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.

Sabina A Schneider, Paulo D'Amora, Steven S Evans, Paul Kent, Tom Stockwell, Vikrant S Bakaya, Paula J Bernard, Federico R Francisco, Luisa Torres, John Henry and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sabina A SchneiderNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Paulo D'AmoraNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.ORCID 0000-0003-2341-5340
Steven S EvansNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Paul KentFibroFighters Foundation, 31805 Temecula Parkway #D7-512, Temecula, CA 92592, USA.ORCID 0000-0001-5893-0313
Tom StockwellFibroFighters Foundation, 31805 Temecula Parkway #D7-512, Temecula, CA 92592, USA.
Vikrant S BakayaNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Paula J BernardNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Federico R FranciscoNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Luisa TorresNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
John HenryNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.
Ismael D C G SilvaGynecology Department, School of Medicine of the Federal University of São Paulo (EPM-UNIFESP), Rua Pedro de Toledo 781, São Paulo 04039-032, SP, Brazil.
Robert A NagourneyNagourney Cancer Institute, 750 East 29th Street, Long Beach, CA 90806, USA.

Funding

Fibrofighters.org NA
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug combination therapyex vivo drug sensitivity testingfibrolamellar carcinomafunctional precision oncologymetabolic profilemetabolomicspersonalized cancer treatmentprogrammed cell deathrare liver cancer

Identifiers

PMID42279327
PMCPMC13255816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.